US-based Cornerstone Therapeutics has entered into an agreement to acquire the US marketing rights to Chiesi Farmaceutici's BETHKIS (Tobramycin Inhalation Solution), designed for the treatment of cystic fibrosis patients with Pseudomonas ...
Tags: US-based Cornerstone Therapeutics, Chiesi Farmaceutici's BETHKIS